BlackThorn Therapeutics scores $40 mln Series A
South San Francisco-based BlackThorn Therapeutics, a treatment developer for neurobehavioral disorders, has raised $40 million in Series A financing. ARCH Venture Partners led the round with participation from other investors that included Johnson & Johnson Innovation – JJDC, Inc, Altitude Life Science Ventures, Mercury Fund and Alexandria Real Estate Equities.
20 October 2016•1 min read
